|
Kardami E.
SELECTED
PEER-REVIEWED PUBLICATIONS
1.
Kardami E
and Fandrich RR. Basic fibroblast growth
factor in atria and ventricles of the vertebrate heart. J Cell Biology 109:1865-1875, 1989
2.
Pasumarthi SKB, Kardami
E and Cattini PA. High and low
molecular weight FGF-2 increase proliferation of neonatal rat cardiac myocytes
but have differential effects on
binucleation and nuclear morphology.
Circ Res 78:126-136, 1996
3.
Doble BW, Bosc D, Litchfield D and Kardami E. Fibroblast growth
factor-2 decreases metabolic coupling and stimulates phosphorylation as well as
masking of connexin43 epitopes in cardiac myocytes. Circ Res 79:647-658, 1996
4.
Padua RR, Merle P-L, Doble BW, Yu C-H, Zahradka P,
Pierce GN, Panagia V and Kardami E. Fibroblast growth factor-2-induced
negative inotropism and cardioprotection are inhibited by chelerythrine;
involvement of sarcolemmal calcium-independent protein kinase C. J Mol Cell Cardiol 30:2695-2709, 1998
5.
Sheikh F,
Fandrich RR, Kardami E and Cattini
PA. Overexpression of long and short
FGFR-1 isoforms results in FGF-2-mediated proliferation in neonatal cardiac myocyte cultures. Cardiovasc Res 42:696-705, 1999
6.
Doble BW, Ping P and Kardami E. The epsilon
subtype of protein kinase C is required for cardiomyocyte connexin-43 phosphorylation. Circ Res 86:293-301, 2000
7.
Sheikh F, Sontag DP, Kardami E and Cattini PA.
Exogenous addition and endogenous overexpression of FGF-2 increases
cardiac myocyte viability after myocardial injury in isolated mouse
hearts. Am J Physiol 280:H1039-H1050,
2001
8.
Sun G-P, Doble BW, Sun J-M, Florkiewicz F, Kirshenbaum
L, Davie JR, Cattini PA and Kardami E. CUG-initiated FGF-2 induces chromatin
compaction in cultured cardiac myocytes and in
vitro. J Cell Physiol 186:457-467,
2001
9.
Jiang Z-S, Padua RR, Ju
H, Doble BW, Jin Y, Hao-J, Cattini PA, Dixon
IMC and Kardami E. Acute protection of the ischemic heart
by FGF-2; involvement of FGF-2 receptors and protein kinase C. Am J Physiol 282:H1071-H1080, 2002
10.
Dang X, Doble BW and Kardami E. The carboxy-tail of connexin-43 localizes to the
nucleus and inhibits cell growth. Mol
Cell Biochem 242, 35-38, 2003
11.
Jeyaraman M, Tanguy S, Fandrich RR, Lukas A and Kardami E. Ischemia-induced dephosphorylation of
cardiomyocyte connexin-43 is reduced by okadaic acid and caliculin A but not
fostriecin. Mol Cell Biochem
242:129-134, 2003
12.
Doble BW, Dang
X, Ping P, Fandrich RR, Nickel BE, Jin Y, Cattini PA and Kardami E. Phosphorylation of serine 262 in the gap
junction protein connexin-43 regulates DNA synthesis in cell-cell contact
forming cardiomyocytes. J Cell
Sci 2004 117:507-514, 2004
13.
Jiang ZS,
Srisakuldee W, Soulet F, Bouche G and Kardami E. Non-angiogenic FGF-2 protects the ischemic
heart from injury, in the presence or absence of reperfusion. Cardiovasc
Res 62:154-166, 2004
14.
Jimenez
SK, Sheikh F, Jin Y, Detillieux
KA, Dhaliwal J, Kardami E and
Cattini PA. Transcriptional regulation of FGF-2 gene expression in cardiac
myocytes. Cardiovasc Res 62, 548-557, 2004
15.
Kardami E,
Jiang ZS, Jimenez SK, Hirst CJ, Sheikh F, Zahradka P and
Cattini PA. The role of FGF-2 isoforms in cardiac hypertrophy. Cardiovasc Res 63:458-466, 2004
16.
Jiang ZS, Jeyaraman M, Wen G-B, Fandrich RR, Dixon IAC, Cattini PA and
Kardami
E. High- but not
low-molecular weight FGF-2 causes cardiac hypertrophy in vivo: Possible involvement of cardiotrophin-1. J
Mol Cell Cardiol 42:222-233, 2007.
17.
Kardami E,
Dang X, Iacobas DA, Nickel BE, Jeyaraman M, Srisakuldee W, Makazan J, Tanguy S,
Spray DC.
The role of connexins in controlling cell growth and gene expression Progress in Biophysics and Molecular Biology,
94, 245-264, 2007 .
18.
Ma X, Dang X, Claus P, Hirst, Fandrich RR, Jin Y, Grothe C, Kirshenbaum L, Cattini PA and Kardami
E. Chromatin compaction and cell
death by high molecular weight FGF-2 depend on its nuclear localization,
intracrine activation of ERK1/2 and engagement of mitochondria. Journal of
Cellular Physiology 213, 690-698, 2007.
19.
Kardami E, Detillieux K, Ma X, Jiang ZS, Santiago
JJ, Jimenez SK, Cattini PA. FGF-2 and cardioprotection. Heart Fail Rev.
2007 Dec;12(3-4):267-77.
|
